[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,165,894
  • Shares Outstanding, K 118,014
  • Annual Sales, $ 1,239 M
  • Annual Income, $ 210,000 K
  • EBIT $ 420 M
  • EBITDA $ 440 M
  • 60-Month Beta 0.86
  • Price/Sales 3.41
  • Price/Cash Flow 13.17
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 45.90% (+2.73%)
  • Historical Volatility 35.41%
  • IV Percentile 10%
  • IV Rank 31.24%
  • IV High 97.01% on 04/15/26
  • IV Low 22.67% on 09/05/25
  • Expected Move (DTE 21) 1.36 (3.90%)
  • Put/Call Vol Ratio 0.93
  • Today's Volume 83
  • Volume Avg (30-Day) 373
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 17,483
  • Open Int (30-Day) 33,571
  • Expected Range 33.51 to 36.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.93
  • Number of Estimates 1
  • High Estimate $0.93
  • Low Estimate $0.93
  • Prior Year $0.72
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.49 +1.10%
on 08/28/26
41.65 -16.28%
on 07/29/26
-6.12 (-14.93%)
since 07/28/26
3-Month
32.41 +7.59%
on 06/02/26
42.81 -18.55%
on 06/26/26
-1.74 (-4.75%)
since 05/28/26
52-Week
22.22 +56.93%
on 09/18/25
42.81 -18.55%
on 06/26/26
+10.99 (+46.02%)
since 08/28/25

Most Recent Stories

More News
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals...

INDV : 34.87 (-1.22%)
SUPN : 43.73 (-1.04%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

NEW YORK , Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

INDV : 34.87 (-1.22%)
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

INDV : 34.87 (-1.22%)
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenues Enhanced financial position and free cash flow...

INDV : 34.87 (-1.22%)
SUPN : 43.73 (-1.04%)
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual...

INDV : 34.87 (-1.22%)
SUPN : 43.73 (-1.04%)
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter...

INDV : 34.87 (-1.22%)
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to...

INDV : 34.87 (-1.22%)
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Q1’26 Total Net Revenue of $317 Million, Up 19% YoYQ1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and...

INDV : 34.87 (-1.22%)
Indivior Reports Tomorrow With SUBLOCADE Deceleration Already Priced In But Margin Promise Still Unproven

Barchart Research What to Expect from INDV Earnings INDV Generated April 29, 2026 Current Price $34.15 EPS Estimate $$0.64 Consensus Rating Strong Buy Average Move 11.78% Indivior Reports Tomorrow With...

INDV : 34.87 (-1.22%)
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional...

INDV : 34.87 (-1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Indivior Pharmaceuticals Inc., together with its subsidiaries, develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders principally in the United States, Europe, Canada, Australia and internationally. Indivior Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 36.41
2nd Resistance Point 35.95
1st Resistance Point 35.41
Last Price 34.87
1st Support Level 34.41
2nd Support Level 33.95
3rd Support Level 33.41

See More

52-Week High 42.81
Fibonacci 61.8% 34.94
Last Price 34.87
Fibonacci 50% 32.51
Fibonacci 38.2% 30.09
52-Week Low 22.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.